Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Background Acute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low‐intensity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2021-12, Vol.127 (23), p.4421-4431
Hauptverfasser:	Kantarjian, Hagop M., Begna, Kebede H., Altman, Jessica K., Goldberg, Stuart L., Sekeres, Mikkael A., Strickland, Stephen A., Arellano, Martha L., Claxton, David F., Baer, Maria R., Gautier, Marc, Berman, Ellin, Seiter, Karen, Solomon, Scott R., Schiller, Gary J., Luger, Selina M., Butrym, Aleksandra, Gaidano, Gianluca, Thomas, Xavier G., Montesinos, Pau, Rizzieri, David A., Quick, Donald P., Venugopal, Parameswaran, Gaur, Rakesh, Maness, Lori J., Kadia, Tapan M., Ravandi, Farhad, Buyse, Marc E., Chiao, Judy H.
Format:	Artikel
Sprache:	eng
Schlagworte:	5-aza-2'-deoxycytidine Acute myeloid leukemia acute myeloid leukemia (AML) Aged Arabinonucleosides Azacitidine Blood Bone marrow Chemotherapy Cytosine - analogs & derivatives Cytosine - therapeutic use Decitabine Disorders Erythrocytes Humans hypomethylation Intravenous administration Leukemia Leukemia, Myeloid, Acute Leukocytes Myelodysplastic syndrome Myelodysplastic syndromes Myeloid leukemia Neoplasms Nucleoside analogs Older people Oncology Oral administration Randomization Remission Remission (Medicine) sapacitabine Subgroups Survival therapy Transfusion Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!